home / stock / acxp / acxp news


ACXP News and Press, Acurx Pharmaceuticals Inc. From 07/28/21

Stock Information

Company Name: Acurx Pharmaceuticals Inc.
Stock Symbol: ACXP
Market: NASDAQ
Website: acurxpharma.com

Menu

ACXP ACXP Quote ACXP Short ACXP News ACXP Articles ACXP Message Board
Get ACXP Alerts

News, Short Squeeze, Breakout and More Instantly...

ACXP - Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option PR Newswire STATEN ISL...

ACXP - Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals,...

ACXP - Microcaps mostly among premarkets gainers

Alterity Therapeutics Limited (ATHE) +57% on a new patent by USPTO.Birks Group (BGI) +49% on re-opening of its retail stores across Canada.Wunong Net Technology Company (WNW) +46%.Spero Therapeutics (SPRO) +23% on $40M equity investment from Pfizer.Bridgeline Digital (BLIN) +21...

ACXP - Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference - Ibezapolstat, the first of a novel class of antibiotics, DNA polymerase IIIC inhibitors, is currently commencing a Phase 2b clinical trial in patients with CDI ...

ACXP - Acurx Pharmaceuticals closes $15 IPO

Antibiotics focused Acurx Pharmaceuticals ([[ACXP]] +0.3%) has completed its $15M IPO, which also included a full exercise by the underwriters to purchase an additional 375K shares at $6 per share.The company says net proceeds after expenses is $14.8M.Alexander Capital was lead book-runner wi...

ACXP - ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES PR Newswire STATEN ISLAND, N.Y. , June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: A...

ACXP - Intellia Therapeutics, Verve Therapeutics leads healthcare gainers; CEL-SCI, Acurx Pharmaceuticals among major losers

Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...

ACXP - Lufax Holding, Alnylam Pharmaceuticals among premarket losers' pack

Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...

Previous 10 Next 10